Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;13(30):2745-2758.
doi: 10.2217/fon-2017-0284. Epub 2017 Sep 12.

Pembrolizumab in the treatment of advanced urothelial cancer

Kevin T Lundgren  1 , Matthew S Farina  1 , Joaquim Bellmunt  1   2
Affiliations
Review

Pembrolizumab in the treatment of advanced urothelial cancer

Kevin T Lundgren et al. Future Oncol. 2017 Dec.

Abstract

Pembrolizumab is a humanized monoclonal antibody that targets PD-1. In the Phase III trial KEYNOTE-045, pembrolizumab was associated with a significant overall survival benefit when compared with docetaxel, paclitaxel and vinflunine in second line metastatic urothelial carcinoma (UC). Additionally, in the first line, early results from an interim analysis of the Phase II trial Keynote-052 study indicated that pembrolizumab is efficacious for cisplatin-ineligible patients. Based on data from these trials, pembrolizumab was the most recent among the five checkpoint inhibitors tested in UC to be approved by the US FDA in May 2017. It was granted regular approval for patients with advanced-stage UC who progress after receiving platinum-based chemotherapy and accelerated approval in the first line for patients who are ineligible to receive cisplatin.

Keywords: immune checkpoint inhibition; locally advanced and metastatic urothelial carcinoma (UC); pembrolizumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources